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ABSTRACT
The efficacy and safety of lenvatinib (LEN) as a second/third-line treatment 
for unresectable hepatocellular carcinoma (HCC) after sorafenib (SOR) therapy 
remains unknown. We evaluated the outcomes of second/third-line LEN treatment, 
investigated the sensitivity of a SOR-resistant HCC cell line (PLC/PRF5-R2) to LEN, 
and assessed their signal transduction pathways by protein array analysis. We 
retrospectively enrolled 57 patients with unresectable HCC. Fifty-three radiologically 
evaluated patients comprised 34 molecular-targeted agent (MTA)-naive (first-line), 
nine intolerant to SOR (second-line), and 10 resistant to regorafenib (third-line). The 
objective response rates (ORRs) were 61.8% in first-line, 33.3% in second-line, and 
20.0% in third-line groups. The overall survival (OS) in the first-line was significantly 
longer than that in the third-line group (p < 0.05). Patients with better liver functional 
reserves (child score, ALBI grade) exhibited higher ORR and longer OS. The IC50 of 
LEN against PLC/PRF5-R2 was significantly higher than that against PLC/PRF5. LEN 
significantly inhibited more LEN-related signal transduction pathways in PLC/PRF5 
than in PLC/PRF5-R2 cells. This suggests that LEN is active and safe as a second/
third-line treatment for unresectable HCC. LEN seems more effective for patients 
with HCC with better hepatic reserve functions or before MTA-resistance is acquired 
because of the partial cross-resistance to SOR.
INTRODUCTION
Hepatocellular carcinoma (HCC) is reportedly 
the fifth most commonly-diagnosed malignancy and the 
second leading cause of cancer-related death worldwide 
[1]. For patients with unresectable advanced HCC, 
sorafenib (SOR) was the first recommended systemic 
therapy to demonstrate a survival benefit with an adequate 
safety profile [2, 3]. SOR is an oral molecular-targeted 
agent (MTA) that blocks RAF kinase, vascular endothelial 
growth factor (VEGF) receptors, and the platelet-derived 
growth factor (PDGF) receptors KIT and fms-related 
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tyrosine kinase 3 (FLT3). A phase III SHARP trial showed 
a median overall survival (mOS) of 10.7 months and a 
disease control rate (DCR) of 43% in the SOR treatment 
group of unresectable HCC patients with well-preserved 
liver function. However, the benefits of SOR were not 
sustained as the median time-to-progression (mTTP) was 
only 5.5 months. Subsequently, a randomized, placebo-
controlled, phase III RESORCE trial reported that 
regorafenib (REG), an oral MTA, resulted in survival 
benefits for patients with advanced HCC who were 
progressing while on SOR. In this trial, REG showed a 
2.8-month improvement in mOS, with a 38% reduction 
in the risk of death [4]. Thus, REG has been the standard 
second-line chemotherapy for patients refractory to SOR. 
However, the frequency of advanced HCC patients for 
whom REG is indicated is reportedly only 30.6‒37% 
[5–8], and more than half of these patients are not able 
to receive second-line treatment. Recently, a phase III 
REACH-2 trial demonstrated that ramucirumab (RAM) 
in advanced HCC patients with baseline α-fetoprotein 
levels ≥ 400 ng/ml after SOR failure showed significant 
improvements in mOS [8.5 vs. 7.3 months; hazard ratio: 
0.710; 95% confidence interval (CI): 0.531–0.949]. 
However, the patients for whom RAM is indicated are 
limited to a proportion of only 23.3% [9].
Furthermore, cabozantinib (CAB), an oral MTA for 
MET, VEGFR2, and RET, was shown to be superior than 
the placebo in a phase III CELESTIAL trial (mOS: 10.2 
vs. 8.0 months; hazard ratio: 0.76; 95% CI: 0.63–0.92) 
of advanced HCC patients with SOR resistance. In this 
study, a relatively high frequency of Grade 3 or 4 adverse 
events (68%) was observed after CAB treatment, such as 
palmar–plantar erythrodysesthesia (17%), hypertension 
(16%), and increased aspartate aminotransferase levels 
(12%) [10].
A recent phase III REFLECT trial indicated that 
lenvatinib (LEN) was not inferior to SOR as a first-line 
treatment for unresectable HCC [11]. LEN is an oral MTA 
that targets VEGF receptors 1–3, FGF receptors 1–4, 
PDGF receptor α, RET, and KIT [12–16]. The REFLECT 
trial showed a mOS of 13.6 months and an mTTP of 8.9 
months, where the objective response rate (ORR) was 
40.6% for patients of the LEN group. Thus, LEN has 
been approved in Japan and other countries as a first-line 
systemic treatment for patients with unresectable advanced 
HCC [11]. Due to the promising efficacy, tolerability, and 
cost-effectiveness of LEN [17], it has been used not only 
as a first-line treatment but also as a second-line treatment 
for patients intolerant to SOR and as a third-line treatment 
following SOR and REG failure in clinical practice. 
However, there have only been a few reports regarding 
the efficacy and adverse effects of LEN when used as a 
second- or third-line treatment for advanced HCC [18, 19]. 
Especially, little is known about the clinical characteristics 
of HCC patients that receive potential therapeutic benefits 
from second- or third-line LEN treatment.
Currently it is not evident whether LEN or SOR 
should be used as the first-line therapy for advanced 
HCC. However, both drugs are similar MTAs, and some 
components of the target molecules (VEGFR, PDGFR, 
KIT) are common to both agents. Therefore, it is highly 
plausible that they might generate cross resistance to 
each other. In this context, it is expected that the efficacy 
of LEN as a second- or third-line treatment for HCCs, 
beyond SOR, could be less than that of LEN as a first-
line treatment. Moreover, it is unclear which signal 
transduction pathways are associated with the efficacy of 
LEN against HCC cells that acquire SOR resistance.
Accordingly, we evaluated the characteristics, 
therapeutic efficacy, and safety of LEN as a second- and 
third-line treatment and also as a first-line treatment for 
unresectable HCC patients in clinical practice. Moreover, 
to expand upon these clinical findings in vitro, we assessed 
the anti-tumor activity of LEN using a SOR-resistant cell 
line and performed a comprehensive phosphorylated protein 
array analysis associated with 377 signal transduction 
pathways using SOR-resistant and parental HCC cells.
RESULTS
Patient characteristics
A total of 57 patients with unresectable HCC who 
had received LEN were enrolled in this study. However, 
of these, four patients were excluded from the analysis 
because they could not be evaluated using modified 
Response Evaluation Criteria in Solid Tumors (mRECIST) 
measurements due to renal failure. Thus, 53 patients were 
retrospectively analyzed. Baseline characteristics of these 
patients are listed in Table 1. The median observation 
period following the initiation of treatment with LEN was 
266 (111–603) days. The median age of the patients was 
71 years (range, 47–85 years). Of all patients, 14 (26.4%) 
were HBV antigen-positive and 22 (41.5%) were HCV 
antibody-positive and the male population was apparently 
larger than the female cohort.
The Eastern Cooperative Oncology Group 
performance status (ECOG PS) was 0 in 48 patients 
(90.6%). The median alpha-fetoprotein (AFP) value was 
37 ng/ml (range 2–568100) and Child-Pugh scores before 
treatment were 5 points in 30 patients and 6 points in 23 
patients. ALBI grades before treatment were 1 point in 
22 patients and 2 points in 31 patients. LEN therapy was 
initiated at Barcelona Clinic Liver Cancer (BCLC) stage 
B in 37 patients and at stage C in 16 patients. The median 
number of cases of transarterial chemoembolization 
(TACE) before treatment with LEN was 1 (0‒9). Among 
the 53 patients, 34 were MTA-naive (first-line), nine were 
intolerant to SOR (second-line), and 10 were resistant to 
SOR and REG (third-line). The median duration of follow-
up in each group was as follows: 255 (118–603) days for 
first-line, 391 (111–603) days for second-line, and 265 
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(132–507) days for third-line. There were no significant 
differences in patient characteristics between those 
with and without a previous history of MTA treatment, 
including hepatic reserve function and tumor burden.
Response to LEN
Fifty-three patients had measurable lesions that 
could be evaluated by enhanced computed tomography/
magnetic resonance imaging (CT/MRI) at 8 weeks after 
the initiation of LEN treatment. Of these 53 patients, 
two exhibited a complete response (CR) (3.8%), 24 had 
a partial response (PR) (45.3%), 25 had stable disease 
(SD) (47.2%), and two presented with progressive 
disease (PD) (3.8%). The ORR and DCR were 49.1% 
(26/53) and 96.2% (51/53), respectively (Supplementary 
Table 1). Regarding the response in each treatment-line 
group, ORRs in the first-line group (61.8%; 21/34) were 
higher than those in the second-line group (33.3%, 3/9; p 
= 0.28) and those in the third-line group (20.0%, 2/10; p 
= 0.27; Table 2). Moreover, the ORR with BCLC stage 
B (20/37, 54.1%) was higher than that with BCLC stage 
C (6/16, 37.5%). In terms of hepatic reserve functions, 
the ORR in the Child-Pugh score of 5 group (16/30, 
53.3%) was higher than that with a Child-Pugh score of 
6 (10/23, 43.5%). Likewise, ORR in the ALBI grade 1 
group (14/22, 58.8%) was higher than that in the ALBI 
grade 2 group (12/31; 38.7%; Table 2). The mTTP of the 
53 patients was 8.5 months (95% CI: 6.9–13.8 months; 
Supplementary Figure 1). The TTP in the first-line group 
was significantly longer than that in the second-line group 
(p < 0.05; Figure 1A). The TTP in the first-line group was 
significantly longer than that in the third-line group (p < 
0.01). The TTP in the BCLC stage B group tended to be 
longer than that in the stage C group (p = 0.07; Figure 
1B). Similarly, TTP in the ALBI Grade1 group was 
significantly longer than that in the ALBI Grade2 group 
(p < 0.05; Figure 1C). Further, TTP in cases with a Child-
Pugh score of 5 was significantly longer than that in cases 
with a Child-Pugh score of 6 (p < 0.01; Figure 1D).
The median OS of the 53 patients was NA (95% 
CI:19.8–NA months; Supplementary Figure 2). The 
median OS in the first-, second-, and third-line groups 
were not reached. The OS in the first-line group was 
significantly longer than that in the third-line group (p < 
0.05; Figure 2A). There was no significant difference in 
OS between the first- and second-line groups. The OS in 
the BCLC stage B group was significantly longer than that 
in the stage C group (p < 0.01; Figure 2B). The OS in the 
ALBI Grade1 group tended to be longer than that in the 
ALBI Grade2 group (p < 0.05; Figure 2C). Moreover, OS 
with a Child-Pugh score of 5 was significantly longer than 
that with a score of 6 (p < 0.05; Figure 2D).
Safety
Grade 4 adverse effects (AEs) were not observed 
during the observation period. The most common all-
grade drug-related AEs were hypertension (54.7%; 
29/53), proteinuria (47.2%; 25/53), fatigue (49.1%; 
Table 1: Characteristics of patients with unresectable hepatocellular carcinoma treated with 
lenvatinib






(n = 10) p-value
Age, median [range], (years) 71 [47–85] 72 [53–85] 70 [61–80] 66 [47–83] 0.45
Sex (male/female), n 44/9 30/4 7/2 7/3 0.38
Etiology (HBV/HCV/NBNC), n 14/22/17 10/12/12 2/4/3 2/6/2 0.87
ECOG PS (0/1), n 48/5 32/2 7/2 10/0 0.24
Platelets, median [range], (104/μl) 14.4 [6.2–31.8] 14.4 [6.2–31.8] 16.3 [9.0–25.7] 11.4 [6.2–23.7] 0.45
M2BpGi [range] (C. O. I) 1.54 [0.44–13.1] 1.25 [0.48–5.76] 1.59 [0.44–13.1] 2.23 [0.58–5.4] 0.17
Child-Pugh score (5/6/7/8), n 30/23/0/0 22/12/0/0 5/4/0/0 3/7/0/0 0.15
ALBI Grade (1/2/3), n 22/31/0 13/21/0 4/5/0 1/9/0 0.08
Number of intrahepatic lesions (None/1/2–7/> 7) 0/6/23/24 0/4/17/13 0/1/4/4 0/1/2/7 0.70
Maximum size of intrahepatic lesion (None/≤ 
50/> 50) (mm) 0/42/11 0/26/8 0/7/2 0/9/1 0.79
Portal vein invasion (absent/present), n 47/6 30/4 7/2 9/1 0.72
Extrahepatic spread (absent/present), n 42/11 29/5 5/4 8/2 0.16
AFP, median [range] (ng/ml) 37 [2–568100] 12 [2–568100] 414 [4–2262] 37 [4–5050] 0.73
BCLC stage (B/C), n 37/16 24/10 5/4 8/2 0.51
Previous treatment times of TAE/TACE [range] 1 [0–9] 1 [1–6] 2 [0–9] 2 [1–6] 0.10
Initial dose of Lenvatinib (12/8/4), (mg), n 30/22/1 23/10/1 3/6/0 4/6/0 0.13
Abbreviations: HBV, hepatitis B virus; HCV, hepatitis C virus; NBNC, non B non C; ECOG PS, Eastern Cooperative Oncology Group performance status; 
M2BPGi, mac-2 binding protein glycosylation isomer; ALBI, albumin-bilirubin; AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; TAE/TACE, 
transcatheter embolization/chemoembolization.
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26/53), appetite loss (37.7%; 20/53), and palmar-plantar 
erythrodysesthesia (26.4%; 14/53; Table 3). The most 
common grade 3 drug-related AEs were proteinuria 
(24.5%, 13/53), hypertension (15.1%, 8/53), fatigue 
(7.5%, 4/53), and diarrhea (3.8%, 2/53). There were no 
significant differences in LEN-related AEs among each 
treatment group. Moreover, the frequencies of LEN-
related AEs were higher in the ALBI Grade2 group than 
in the ALBI Grade1 group (Table 4). Among them, the 
frequency of fatigue was significantly higher in patients 
in the ALBI-2 group (23/31, 74.2%) than in those in 
the ALBI-1 group (3/22 13.6%; p < 0.01). Similar AE 
results were observed between groups comprising Child-
Pugh scores of 5 and 6 (data not shown). Treatment with 
LEN was discontinued due to AEs in only three patients. 
All AEs were controlled by appropriate dose reduction 
or care.
Drug administration
The relative dose intensity (RDI) in the first-, 
second-, and third-line groups was 83.1%, 73.6%, 
and 73.5%, respectively. Treatment continued for 12 
weeks in all cases, except in one case of PD and three 
cases of withdrawal due to AEs (two cases of grade 3 
fatigue). During 12 weeks of observation, AEs led to 
the interruption of LEN administration in eight (15.0%) 
patients and dose reduction in 13 (24.5%).
Figure 1: Kaplan–Meier analysis of progression-free survival among patients with advanced hepatocellular carcinoma 
treated with lenvatinib according to treatment lines and hepatic functional reserve. (A) First/second/third-line groups. (B) 
Barcelona Clinic Liver Cancer (BCLC) stage B and C groups. (C) Albumin-bilirubin (ALBI) grade 1 and 2 group (D) Child-Pugh score 5 
and 6 groups.
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In vitro viability of the SOR-resistant cell line 
after LEN treatment
To confirm our clinical observations and to analyze 
mechanisms underlying the sensitivity of HCC cells to 
LEN in vitro, we first performed a cell viability assay 
using previously established PLC/PRF5 and SOR-resistant 
PLC/PRF5-R2 cell lines [20]. The IC50 value of LEN 
towards PLC/PRF5 cells was 6.4 μM, and this value was 
consistent with those of previous reports [20]. However, 
for SOR-resistant PLC/PRF5-R2 cells, the IC50 value of 
LEN was 30 μM, which was significantly higher than that 
with the parental PLC/PRF5 cells (p < 0.05; Figure 3A). 
These findings suggested that PLC/PRF5-R2 cells might 
show partial cross-resistance to LEN.
In vitro signal transduction pathway analysis in 
SOR-resistant cell lines
LEN reportedly inhibits the phosphorylation of 
tyrosine-kinases such as FGF receptors, VEGF receptors, 
and the PDGF receptors RET and KIT [12–15]. Therefore, 
we investigated the degree of protein phosphorylation 
related to LEN-related signal transduction pathways 
in response to LEN using a comprehensive protein 
phosphorylation array (Supplementary Figure 3). A 
representative heatmap of array results including cluster 
analysis is shown in Supplementary Figure 4. The 
heatmap demonstrated that protein phosphorylation levels 
in all 377 signaling pathways were clearly distinguished 
and clustered between PLC/PRF5 and PLC/PRF5-R2 
cells following treatment with LEN. The number of 
LEN-related signal transduction pathways that were 
significantly altered following LEN treatment was 16 
including 12 related to FGFR, three to PDGF, and one to 
VEGF, whereas only three FGFR pathways were altered 
in PLC/PRF5-R2 cells (Figure 3B). These results further 
indicated that PLC/PRF5-R2 cells show cross-resistance 
to LEN.
In vitro FRS2-related pathway analysis in the 
SOR-resistant cell line
The adaptor protein fibroblast growth factor 
receptor substrate 2 (FRS2) is reportedly an essential 
downstream component of the FGFR signaling pathway 
and acts as a hub linking several signaling pathways to 
ultimately activate FGFRs [21]. Therefore, we examined 
the inhibitory effects of LEN on the phosphorylation of 
63 FRS2-related pathways among a total of 377 pathways 
involved in signal transduction (Supplementary Table 2) 
in PLC/PRF5 and PLC/PRF5-R2 cell lines using a 
phosphorylation array (Figure 3C). LEN suppressed the 
phosphorylation of FRS2 protein in those pathways in 
both cell lines. However, the degree of suppression was 
significantly higher in PLC/PRF5 cells than in PLC/
PRF5-R2 cells (p < 0.01, Welch’s t-test); this indicated 
that the degree of LEN-mediated inhibition of FRS2-
related signaling pathways in PLC/PRF5-R2 cells was 
significantly lower than that in PLC/PRF5 cells. Thus, it 
was evident that SOR-resistant HCC cells show partial 
cross-resistance to LEN based on resistance to the LEN-
mediated inhibition of FGFR signaling pathways.
DISCUSSION
In this retrospective study, we demonstrated the 
therapeutic efficacy and safety of LEN as a second- and 
third-line treatment, particularly for patients intolerant to 
SOR (second-line) and as a first-line treatment for HCC. 
Table 2: Response to treatment with lenvatinib for advanced hepatocellular carcinoma according 
to treatment line, stage, and hepatic functional reserve
Evaluation (mRECIST) CR PR SD PD ORR (%) DCR (%)
Treatment line
 First-line (n = 34) 1 (2.9) 20 (58.8) 12 (35.3) 1 (2.9) 61.8 97.1
 Second-line (n = 9) 1 (11.1) 2 (22.2) 5 (55.5) 1 (14.3) 33.3 88.8
 Third-line (n = 10) 0 (0) 2 (20.0) 8 (80.0) 0 (0) 20.0 100
BCLC stage
 B (n = 37) 2 (5.4) 18 (48.6) 17 (45.9) 0 (0) 54.1 100
 C (n = 16) 0 (0) 6 (37.5) 8 (50.0) 2 (12.5) 37.5 87.5
Child-Pugh score
 5 (n = 30) 2 (6.7) 14 (46.7) 12 (40.0) 2 (6.7) 53.3 93.3
 6 (n = 23) 0 (0) 10 (43.5) 13 (56.5) 0 (0) 43.5 100
ALBI grade
 1 (n = 22) 1 (4.5) 13 (59.0) 6 (27.2) 2 (9.1) 63.6 91.0
 2 (n = 31) 1 (3.2) 11 (35.5) 19 (61.3) 0 (0) 38.7 100
Abbreviations: mRECIST, modified response evaluation criteria in solid tumors; BCLC, Barcelona Clinic Liver Cancer; ALBI, albumin-bilirubin; CR, 
complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, overall response rate; DCR, disease control rate.
Oncotarget2536www.oncotarget.com
Moreover, our results suggested that treatment with LEN, 
while maintaining better hepatic functional reserves, 
might exert more beneficial effects on the prognosis 
of patients with advanced HCC in a clinical setting. 
Furthermore, our in vitro experiments revealed that the 
SOR-resistant cell line PLC/PRF5-R2 was partially cross-
resistant to LEN. LEN significantly inhibited 16 signal 
transduction pathways including 12 FGFR pathways in 
parent PLC/PRF5 cells but inhibited only a few pathways 
in PLC/PRF5-R2 cells. These results support our clinical 
observations indicating that the response rate of third-line 
LEN treatment was rather low compared to that of first-
line treatments.
At present, REG, CAB, and RAM have resulted in 
prolonged OS compared to that with placebo for patients 
with SOR-resistant disease [4, 10, 22]. However, there has 
been no clear indication to use these drugs as a second-
line treatment since there is no head-to-head comparison 
available for drugs in this setting. REG has been used only 
to treat patients who are tolerant to SOR treatment, as a 
second-line treatment following SOR, but not for patients 
intolerant to SOR. Approximately one third of patients 
who receive SOR treatment are reportedly intolerant to 
SOR [5–8], and therefore are deemed unsuitable to receive 
substantially effective systemic chemotherapy. Thus, LEN 
shows potential as a second-line treatment for patients 
with unresectable HCC intolerant to SOR.
In this study, the ORRs of LEN in third-line 
treatment (20.0%) were significantly lower than those in 
first-line treatment group (61.8%) and somewhat lower 
than those in the second-line treatment group (33.3%). 
However, DCR in the third-line treatment group was 
highly similar to that with the other-line treatments. 
Likewise, the mTTP and OS in the third-line treatment 
Figure 2: Kaplan–Meier analysis of overall survival among patients with advanced hepatocellular carcinoma treated 
with lenvatinib according to treatment lines and hepatic functional reserve. (A) First-/second-/third-line groups. (B) Barcelona 
Clinic Liver Cancer (BCLC) stage B and C groups. (C) Albumin-bilirubin (ALBI) grade 1 and 2 group (D) Child-Pugh score 5 and 6 groups.
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group were also significantly shorter than those in the 
first-line treatment group and tended to be shorter than 
those in the second-line treatment groups.
To date, there have been no studies investigating 
ORRs for second- and third-line treatment regimens using 
LEN. Hiraoka et al. reported that there were no significant 
differences in the efficacy of LEN for advanced HCC 
between MTA-naïve and MTA-experienced groups [18]. 
Although ORRs for each patient group were not shown, 
the MTA-experienced patients included only 25% (11/44) 
of patients following SOR–REG treatment (third line), 
whereas 75% (33/44) were considered SOR-intolerant 
patients (second line). In this context, it appears that LEN 
is relatively effective for SOR-intolerant patients but less 
effective for patients resistant to SOR–REG treatment. In 
fact, the effects of LEN in our second-line cohort were 
comparable to those with first-line treatment. This might 
be due to the fact that patients administered second-line 
LEN treatment could still be sensitive to MTAs since 
they could not continue SOR treatment due to detrimental 
adverse effects but did not acquire complete resistance to 
SOR. Therefore, it is reasonable to assume that LEN is 
fairly effective for HCC patients intolerant to SOR as a 
second-line treatment.
Our in vitro cell viability assay revealed that the 
IC50 of LEN towards the SOR-resistant cell line (PLC/
PRF5-R2) was significantly higher than that with parental 
PLC/PRF5 cells (p < 0.01; Figure 3A). It is plausible 
that the signaling pathway inhibited by LEN in HCC 
cells was modified during the course of acquiring SOR-
resistance, leading to partial cross-resistance to LEN. In 
general, it is difficult to delineate the multifaceted and 
dynamic pathway regulation in response to MTAs such as 
LEN. Therefore, we employed a comprehensive protein 
phosphorylation array, which can simultaneously measure 
the phosphorylation degrees of 1205 proteins belonging 
to 377 signal transduction pathways (Supplementary 
Figure 3) [23]. As a result, we confirmed that LEN 
mainly inhibited the phosphorylation of 12 FGFR-related 
pathways in parental PLC/PRF5 cells, consistent with 
previous reports showing that LEN selectively suppresses 
the proliferation of HCC cells with activated FGF 
signaling pathways; this is a distinct feature of LEN as 
compared to that with SOR [21]. Conversely, only three 
FGFR-related signaling pathways were significantly 
inhibited in PLC/PRF5-R2 cells, indicating the partial 
resistance of those SOR-resistant cells to LEN. These data 
were further supported by the fact that the phosphorylation 
degree of FRS2, which plays a pivotal role in FGFR-
related pathways, in PLC/PRF5-R2 cells was significantly 
higher than that in parental PLC/PRF5 cells (Figure 3C). 
Thus, our protein array analysis suggests that LEN is less 
effective for HCC patients with resistance to SOR than for 
SOR-naïve patients due to cross-resistance between LEN 
and SOR.
The AE profiles in this study were similar to those in 
previous reports [18, 19, 24], mostly documented during 
first-line treatment. Otherwise, the incidence of AEs with 
second/third line treatment was similar to that with first-
line treatment (Table 3). This might be explained by the 
particular characteristics of LEN, which shows different 
AE spectra from those of both SOR and REG. Moreover, 
treatment with LEN could easily be initiated as a second/
third-line treatment following treatment with SOR or 
REG, even in patients suffering from severe AEs related 
to SOR or REG such as hand–foot syndrome and diarrhea. 
Thus, our data demonstrated the safety and feasibility of 
LEN as a second/third-line treatment for unresectable 
HCC. In addition, the incidence of fatigue in the ALBI-
2 group containing all treatment lines was significantly 
higher than that in the ALBI-1 group (Table 4). This 
fatigue was often the cause of dose reduction and the 
Table 3: Adverse events associated with lenvatinib treatment











Hypertension 29 (54.7) 8 (15.1) 21 (61.8) 7 (20.6) 3 (33.3) 1 (11.1) 5 (50.0) 0 (0) 0.32 0.35
Fatigue 26 (49.1) 4 (7.5) 16 (47.1) 1 (2.9) 3 (33.3) 1 (11.1) 7 (70.0) 2 (20.0) 0.27 0.13
Decreased appetite 20 (37.7) 0 (0) 13 (36.0) 0 (0) 2 (22.2) 0 (0) 5 (50.0) 0 (0) 0.55 —
Decreased platelet count 12 (22.6) 0 (0) 9 (38.2) 0 (0) 2 (22.2) 0 (0) 1 (10.0) 0 (0) 0.57 —
Palmar-plantar erythrodysesthesia 14 (26.4) 0 (0) 7 (20.6) 0 (0) 3 (33.3) 0 (0) 4 (40.0) 0 (0) 0.32 —
Proteinuria 25 (47.2) 13 (24.5) 16 (47.1) 10 (29.4) 3 (33.3) 1 (11.1) 6 (60.0) 2 (20.0) 0.16 0.59
Diarrhea 10 (18.9) 2 (3.8) 4 (11.8) 2 (5.9) 3 (33.3) 0 (0) 3 (30.0) 0 (0) 0.26 1
Increased blood bilirubin 3 (5.7) 0 (0) 1 (2.9) 0 (0) 0 (0) 0 (0) 2 (20.0) 0 (0) 0.16 —
Dysphonia 8 (15.1) 0 (0) 5 (14.7) 0 (0) 3 (33.3) 0 (0) 0 (0) 0 (0) 0.13 —
Elevated-aspartate 
aminotransferase 4 (7.5) 0 (0) 2 (5.9) 0 (0) 1 (11.1) 0 (0) 1 (10.0) 0 (0) 0.61 —
Hypothyroidism 6 (11.3) 0 (0) 4 (11.8) 0 (0) 2 (22.2) 0 (0) 1 (10.0) 0 (0) 0.72 —
Hepatic coma 1 (1.9) — 0 (0) — 1 (11.1) — 0 (0) — 0.36 —
The p-values were calculated with Fisher’s exact test.
Oncotarget2538www.oncotarget.com
Figure 3: In vitro cell viability and signal transduction pathway analysis of sorafenib (SOR)-resistant cell line with 
lenvatinib treatment by a comprehensive protein phosphorylation array. (A) The sensitivities of PLC/PRF5 and PLC/ 
PRF5-R2 to lenvatinib (LEN) were assessed by MTT assays. (B) A list of LEN-related signal transduction pathways significantly altered 
after treatment with LEN in PLC/PRF5 and PLC/PRF5-R2 cells. The 114 LEN related pathways were categorized into “Signaling by 
FGFR”, “Signaling by PDGF”, “Signaling by VEGFR”, and “Signaling by SRC-KIT” among 377 pathways tested. (C) Boxplot analysis of 
degree of phosphorylation of associated proteins belonging to the 63 FRS2-related transduction pathways in PLC/PRF5 and PLC/ PRF5-R2 
cells in response to LEN. The boxes show the interquartile rage with the median value indicated by the horizontal line; whiskers show the 
range and circles indicate outliers. *p < 0.0014.
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interruption of treatment, especially in the ALBI-2 group. 
Since the ALBI score is calculated from only albumin and 
total bilirubin values, the ALBI-2 group is more likely 
to have lower serum albumin levels, reflecting poorer 
nutrition and performance status, which might more 
readily lead to fatigue in HCC patients [25–27].
In this study, patients with better liver functional 
reserves (Child-Pugh score of 5, ALBI Grade1) showed 
better response to LEN and longer OS. Recently, Ueshima 
and associates analyzed 82 patients with unresectable 
HCCs treated with LEN and reported that ALBI Grade1 
and serum AFP levels < 200 are predictors of a high 
response rate [28]. They also demonstrated that the time 
to treatment failure in patients with better liver functional 
reserves was longer. These patients included 61.0% MTA-
naïve, 24.4% second-line (SOR intolerance), and only 
14.6% third-line treatment patients. They also included 
those with a Child-Pugh score B, as well as those with 
score A, and BCLC stages A, B, and C. Although the 
specific proportions of patients were largely different 
from those in our study, our data on treatment outcomes 
displayed partial similarity to theirs. Patients with better 
liver functional reserves showed better responses, and 
the OS in the Child-Pugh score 5 group was significantly 
longer than that in the Child-Pugh score 6 group. These 
results might be partly explained by the difference in 
RDI. The RDI of LEN in the Child-Pugh score 5 group 
(81.4%) was higher than that in the Child-Pugh score 6 
group (76.5%). Thus, to maximize the therapeutic effect of 
LEN, it should be used in patients with unresectable HCC, 
while liver function is preserved, as with Child-Pugh A 
and ALBI-1 grade patients. Although repeated TACE was 
often performed for the treatment of unresectable HCC 
until recently, LEN treatment should be initiated in HCC 
patients with better liver functional reserves. Eventually, 
in this study, patients with BCLC stage C showed lower 
ORRs and a shorter TTP and OS than those with BCLC 
stage B. One of the reasons is that BCLC stage C cases 
included six patients with portal vein invasion, which 
might be related to the poor outcomes observed.
One limitation of this study was its single-center, 
retrospective design. Of note, the sex distribution of the 
research population was uneven in this cohort. This might 
be due to the fact that the male sex correlates with the 
development of HCC among patients with cirrhosis-
related HCV [29], which was observed at a relatively high 
rate in our cohort.
Another limitation was that the observation period 
was relatively short and the number of analyzed patients 
was small. However, considering that LEN had only been 
approved in Japan for 25 months, our observations at the 
specified cutoff date are adequate to report real-world 
treatment results, especially those related to evaluating 
the initial safety and efficacy of the clinical use of LEN. A 
large-scale prospective study is indispensable to establish 
the efficacy of LEN for second-and third line-treatment 
use in the future. Regarding in vitro experiments, LEN 
exerts its effect by blocking not only FGFR, but also 
PDGFR-α and VEGFR, the latter of which is expressed 
in endothelial cells rather than cancer cells. Therefore, the 
findings should be confirmed using in vivo HCC xenograft 
models, where the anti-angiogenic activity of LEN can be 
evaluated.
In conclusion, we demonstrated that LEN 
monotherapy could be feasible as a second/third-line 
treatment for unresectable HCC and suggest that LEN 
should preferably be applied to patients with better 
functional liver reserves (ALBI-1 or Child score 5) 
to obtain good outcomes. Moreover, LEN was more 
effective in MTA-naïve patients as a first-line treatment 
than in patients administered LEN for second- and third-
line treatment, and particularly in patients on third-line 
treatment after a SOR–REG treatment. These clinical 
data are supported by the in vitro experimental results 
indicating that the SOR-resistant cell line became partially 
cross-resistant to LEN by altering FGFR-related signal 
transduction pathways.
MATERIALS AND METHODS
Patient selection and diagnosis of HCC
This retrospective, observational study evaluated the 
efficacy and safety of LEN (Lenvima®, Eisai Co., Ltd., 
Tokyo, Japan) monotherapy in patients with unresectable 
advanced HCC at Tokushima University Hospital between 
March and December 2018. This study was approved by 
the Ethics Committee of Tokushima University Hospital 
Table 4: The relationship between adverse events and ALBI-grade
Event
ALBI grade n = 53
ALBI-1 n = 22 ALBI-2 n = 31 p-value
Hypertension 11 (50.0) 18 (58.1) 0.59
Fatigue 3 (13.6) 23 (74.2) < 0.01
Decreased appetite 7 (31.8) 13 (41.9) 0.57
Decreased platelet count 4 (18.2) 8 (25.8) 0.74
Palmar-plantar erythrodysesthesia 5 (22.7) 9 (29.0) 0.76
Proteinuria 10 (45.5) 15 (48.4) 1
The p-values were calculated with Fisher’s exact test. Abbreviations: ALBI, albumin-bilirubin.
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(Approval number; 3489). The inclusion criteria were 
based on those of the REFLECT trial. Briefly, eligible 
patients had target lesions defined as measurable based on 
mRECIST [30], an ECOG PS score of 0 or 1 [31], BCLC 
B or C categorizations [32], and Child-Pugh class A. 
Written informed consent was obtained from all patients. 
The diagnosis of HCC was based on guidelines established 
by the Liver Cancer Study Group of Japan [33]. According 
to these guidelines, a diagnosis of HCC was confirmed 
via histology or characteristic radiologic findings such as 
typical arterial enhancement of the tumor followed by a 
washout pattern in the images of the portal venous phase 
or the equilibrium phase obtained by dynamic spiral CT 
imaging or contrast-enhanced MRI.
Treatment with LEN
The initial daily oral doses of LEN given to patients 
weighing ≥ 60, < 60, and < 40 kg were 12, 8, and 4 mg/
day, respectively. The initial daily oral doses of LEN 
given to patients weighing ≥ 60 and < 60 kg were 12 and 
8 mg/day, respectively. For HCC patients weighing < 40 
kg, we started with the initial LEN dose of 4 mg/day and 
confirmed the safety for 1 week, which was followed by 
dosing up to 8 mg/day since there are no reports showing 
the appropriate starting dose for patients weighing 
< 40 kg.
When serious AEs were observed, LEN 
administration was discontinued. Dose interruptions were in 
accordance with medical package inserts for administering 
LEN. Briefly, when Grade3 AEs or unacceptable Grade2 
AEs developed, LEN was discontinued until AEs recovered 
and reverted to a lower grade.
Hepatic reserve function
Hepatic reserve function was assessed according to 
ALBI grading and Child-Pugh classification. ALBI grade 
was calculated based on serum albumin and total bilirubin 
values using the following formula: [ALBI score = (log10 
bilirubin (µmol/L) × 0.66) + (albumin (g/L) × –0.085)] 
and defined by the following scores: ≤ –2.60 = Grade 1, > 
–2.60 to ≤ –1.39 = Grade 2, > –1.39 = Grade 3 [34].
Follow-up and patient outcome
Patients were observed for at least 12 weeks. 
Safety was assessed by recording any adverse drug 
reactions, clinical laboratory tests, physical examination, 
measurement of vital signs, hematological and 
biochemical laboratory testing, and urinalysis. Adverse 
drug reactions were defined according to the Common 
Terminology Criteria for Adverse Events version 5.0. 
Radiologic; responses to therapy were evaluated according 
to mRECIST at the 8th week after starting LEN and every 
8 weeks thereafter. ORR was defined as the sum of CR 
and PR rates. DCR was defined as the sum of CR, PR, 
and SD rates. TTP was defined as the time from the first 
day of administering LEN until the day of radiological 
progression.
Cell culture and viability analysis
The representative human hepatoma cell line PLC/
PRF5 was purchased from the American Tissue Culture 
Collection (ATCC, Manassas, VA, USA). Establishment 
of the SOR-resistant PLC/PRF5 cell line (PLC/PRF5-R2) 
was performed as described previously [20]. Cells were 
grown in Dulbecco’s modified Eagle’s medium (Invitrogen 
Sigma-Aldrich, St. Louis, MO, USA) supplemented with 
10% FBS and 2 mM L-glutamine. Cell viability was 
assessed via a 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyl-
2H-tetrazolium bromide (MTT) assays as described 
previously [20].
Identification of active signal transduction 
pathways by protein array
We used a self-made comprehensive protein 
phosphorylation array that included 1205 proteins 
representing 377 pathways involved in signal 
transduction [23], as described in the supporting 
information (Supplementary Figure 3) to determine the 
phosphorylation status of selected proteins in the active 
signal transduction pathways of HCC cells in the absence 
or presence of LEN.
Statistical analysis
Categorical variables were compared using the 
Fischer’s exact test, whereas continuous variables were 
compared using Mann–Whitney and Kruskal–Wallis 
tests. All significance tests were two-tailed, and statistical 
significance was set at p < 0.05. Kaplan–Meier plots of 
medians (with 95% CIs) were used to estimate TTP. All 
statistical analyses were undertaken using Easy R (EZR) 
version 1.29 (Saitama Medical Center, Jichi Medical 
University, Saitama, Japan).
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